PE20241477A1 - Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii - Google Patents

Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii

Info

Publication number
PE20241477A1
PE20241477A1 PE2024001077A PE2024001077A PE20241477A1 PE 20241477 A1 PE20241477 A1 PE 20241477A1 PE 2024001077 A PE2024001077 A PE 2024001077A PE 2024001077 A PE2024001077 A PE 2024001077A PE 20241477 A1 PE20241477 A1 PE 20241477A1
Authority
PE
Peru
Prior art keywords
tgf
binding
multispecific
brii
binding domain
Prior art date
Application number
PE2024001077A
Other languages
English (en)
Spanish (es)
Inventor
Cecilia Anna Wilhelmina Geuijen
Patrick Mayes
Shaun M Stewart
Liang-Chuan Wang
Original Assignee
Merus Nv
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv, Incyte Corp filed Critical Merus Nv
Publication of PE20241477A1 publication Critical patent/PE20241477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2024001077A 2021-11-19 2022-11-18 Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii PE20241477A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2029844 2021-11-19
PCT/EP2022/082377 WO2023089083A1 (en) 2021-11-19 2022-11-18 Multispecific binding moieties comprising pd-1 and tgf-brii binding domains

Publications (1)

Publication Number Publication Date
PE20241477A1 true PE20241477A1 (es) 2024-07-17

Family

ID=80625531

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024001077A PE20241477A1 (es) 2021-11-19 2022-11-18 Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii

Country Status (18)

Country Link
US (1) US20230159645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433505A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542879A (cg-RX-API-DMAC7.html)
KR (1) KR20240101664A9 (cg-RX-API-DMAC7.html)
CN (2) CN119613560A (cg-RX-API-DMAC7.html)
AR (1) AR127714A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022389596A1 (cg-RX-API-DMAC7.html)
CA (1) CA3231649A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001410A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006325A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240201A (cg-RX-API-DMAC7.html)
EC (1) ECSP24039278A (cg-RX-API-DMAC7.html)
IL (1) IL312214A (cg-RX-API-DMAC7.html)
MX (1) MX2024006018A (cg-RX-API-DMAC7.html)
PE (1) PE20241477A1 (cg-RX-API-DMAC7.html)
TW (1) TW202328180A (cg-RX-API-DMAC7.html)
UY (1) UY40028A (cg-RX-API-DMAC7.html)
WO (1) WO2023089083A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121152809A (zh) * 2023-04-14 2025-12-16 因赛特公司 抗TGFβR2/PD-1双特异性抗体治疗癌症的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
CN110198738A (zh) * 2017-01-07 2019-09-03 默克专利有限公司 用于靶向的TGF-β抑制的给药方案和剂型
TWI917306B (zh) * 2017-07-06 2026-03-11 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的結合分子
TWI887193B (zh) * 2017-07-06 2025-06-21 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业(上海)股份有限公司 四价双特异性抗体、其制备方法和用途
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii

Also Published As

Publication number Publication date
AU2022389596A1 (en) 2024-05-30
ECSP24039278A (es) 2024-07-31
CL2024001410A1 (es) 2024-08-30
MX2024006018A (es) 2024-07-29
CN119613560A (zh) 2025-03-14
AR127714A1 (es) 2024-02-21
JP2024542879A (ja) 2024-11-18
TW202328180A (zh) 2023-07-16
US20230159645A1 (en) 2023-05-25
CA3231649A1 (en) 2023-05-25
IL312214A (en) 2024-06-01
KR20240101664A9 (ko) 2025-12-10
CN118265725A (zh) 2024-06-28
EP4433505A1 (en) 2024-09-25
KR20240101664A (ko) 2024-07-02
CR20240201A (es) 2024-07-15
WO2023089083A1 (en) 2023-05-25
CO2024006325A2 (es) 2024-06-27
UY40028A (es) 2023-05-31

Similar Documents

Publication Publication Date Title
CL2022003788A1 (es) Moléculas de unión contra bcma y usos de las mismas
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
PE20241349A1 (es) Anticuerpos de union a cd3
MX2022003517A (es) Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
MX2019010039A (es) Composiciones y métodos para transducción de tumores.
UY34382A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
DOP2014000074A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
CO2020016151A2 (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
CO2018000414A2 (es) Inmunoconjugados de il22
CO2021014748A2 (es) Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y métodos de fabricación y uso del mismo